WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 8, 2009, 29(27):8734-8742; doi:10.1523/JNEUROSCI.1859-09.2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Google Scholar
Right arrow Articles by Seo, S.
Right arrow Articles by Levandoski, M. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seo, S.
Right arrow Articles by Levandoski, M. M.

 Previous Article  |  Next Article 

Cellular/Molecular
The Positive Allosteric Modulator Morantel Binds at Noncanonical Subunit Interfaces of Neuronal Nicotinic Acetylcholine Receptors

Seungmae Seo, Jonathan T. Henry, Amanda H. Lewis, Nan Wang, and Mark M. Levandoski

Department of Chemistry, Grinnell College, Grinnell, Iowa 50112

Correspondence should be addressed to Mark M. Levandoski, Department of Chemistry, 1116 8th Avenue, Grinnell College, Grinnell, IA 50112. Email: levandos{at}grinnell.edu

We are interested in the positive allosteric modulation of neuronal nicotinic acetylcholine (ACh) receptors and have recently shown that the anthelmintic compound morantel potentiates by enhancing channel gating of the {alpha}3β2 subtype. Based on the demonstration that morantel-elicited currents were inhibited by the classic ACh competitor dihydro-β-erythroidine in a noncompetitive manner and that morantel still potentiates at saturating concentrations of agonist (Wu et al., 2008), we hypothesized that morantel binds at the noncanonical β2(+)/{alpha}3(–) subunit interface. In the present study, we created seven cysteine-substituted subunits by site-directed mutagenesis, choosing residues in the putative morantel binding site with the aid of structural homology models. We coexpressed the mutant subunits and their respective wild-type partners in Xenopus oocytes and characterized the morantel potentiation of ACh-evoked currents, as well as morantel-evoked currents, before and after treatment with a variety of methanethiosulfonate (MTS)-based compounds, using voltage-clamp recordings. The properties of four of the seven mutants, two residues on each side of the interface, were changed by MTS treatments. Coapplication with ACh enhanced the extent of MTS modification for {alpha}3A106Cβ2 and {alpha}3β2S192C receptors. The activities of two mutants, {alpha}3T115Cβ2 and {alpha}3β2T150C, were dramatically altered by MTS modification. For {alpha}3β2T150C, while peak current amplitudes were reduced, potentiation was enhanced. For {alpha}3T115Cβ2, both current amplitudes and potentiation were reduced. MTS modification and morantel were mutually inhibitory: MTS treatment decreased morantel-evoked currents and morantel decreased the rate of MTS modification. We conclude that the four residues showing MTS effects contribute to the morantel binding site.


Received April 19, 2009; revised May 19, 2009; accepted May 31, 2009.

Correspondence should be addressed to Mark M. Levandoski, Department of Chemistry, 1116 8th Avenue, Grinnell College, Grinnell, IA 50112. Email: levandos{at}grinnell.edu






-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-